HopeStage
Back to all studies
CompletedNCT01850953

Varenicline and Smoking Lapses in People With or Without Schizophrenia

About this titleRead the official source — NCT01850953
Medication studyAges 18–55Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2013
Recruitment status
Completed
Enrollment listed in the registry
28
Sponsor
Centre for Addiction and Mental Health
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
From 18 Years to 55 Years
Official registry ID
NCT01850953
Official title
Show the full official title

Evaluating the Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia: Implications for Treatment

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Varenicline and Placebo.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies